Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Ustekinumab-induced Sarcoidosis in a Patient with Psoriatic Arthritis

Author(s): Senol Kobak* and Huseyin Semiz

Volume 15, Issue 2, 2020

Page: [163 - 166] Pages: 4

DOI: 10.2174/1574886315666200316113312

Price: $65

Abstract

Background: Psoriatic Arthritis (PsA) is a chronic inflammatory disease that may affect different joints. Sarcoidosis is a Th-1 cell-related chronic granulomatous disease characterized by non-caseating granuloma formation. The coexistence of both the diseases is a rare entity. Ustekinumab, an IL12 / 23 inhibitor, has shown efficacy and safety in the treatment of PsA.

Objective: This study presents a case with ustekinumab-induced sarcoidosis in a patient with PsA.

Case Report: A 52 years old female patient with complaints of pain and swelling of the wrists, MCP, PIP and DIP joints and skin lesions was referred to our Rheumatology clinic. On her medical history, she had been under follow up for 5 years with the diagnosis of psoriasis and one year ago, she started to receive ustekinumab prescribed by a dermatologist. On physical examination, she had psoriasis skin lesions and arthritis of both wrists, MCP, PIP, DIP joints. Bilateral hilar lymphadenopathies were detected in the chest X-ray and thorax computed tomography. In laboratory tests, acute phase reactants and serum angiotensin-converting enzyme levels were high. Endobronchial ultrasonography biopsy was performed and non-caseating granuloma consistent with sarcoidosis was reported. Ustekinumab was discontinued, methotrexate and low-dose corticosteroid were started. The patient was clinically stable in the 6th month of the treatment and the findings were regressed.

Conclusion: Sarcoidosis development appears to be a new paradoxical effect of ustekinumab therapy, being another biological agent.

Keywords: Sarcoidosis, ustekinumab, psoriatic arthritis, IL12/23 inhibitor, DIP joints, MCP joints.

« Previous Next »
Graphical Abstract

[1]
Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336(17): 1224-34.
[http://dx.doi.org/10.1056/NEJM199704243361706] [PMID: 9110911]
[2]
Chen ES, Moller DR. Etiology of sarcoidosis. Clin Chest Med 2008; 29(3): 365-77.
[http://dx.doi.org/10.1016/j.ccm.2008.03.011] [PMID: 18539232]
[3]
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357(21): 2153-65.
[http://dx.doi.org/10.1056/NEJMra071714] [PMID: 18032765]
[4]
Barnard J, Newman LS. Sarcoidosis: Immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13(1): 84-91.
[http://dx.doi.org/10.1097/00002281-200101000-00014] [PMID: 11148721]
[5]
Cohen AF, Lhote R, Amoura A, et al. Drug-induced sarcoidosis: An overview of the WHO pharmacovigilance database. J Intern Med 2019. Epub ahead of print
[http://dx.doi.org/10.1111/joim.12991] [PMID: 31612562]
[6]
Weber J, Keam SJ. Ustekinumab. BioDrugs 2009; 23(1): 53-61.
[http://dx.doi.org/10.2165/00063030-200923010-00006] [PMID: 19344192]
[7]
Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76.
[http://dx.doi.org/10.1146/annurev.iy.13.040195.001343] [PMID: 7612223]
[8]
Thibodaux RJ, Triche MW, Espinoza LR. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: A drug evaluation and literature review. Expert Opin Biol Ther 2018; 18(7): 821-7.
[http://dx.doi.org/10.1080/14712598.2018.1492545]
[9]
Puig L. Paradoxical reactions: Anti-Tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018; 53: 49-63.
[http://dx.doi.org/10.1159/000479475] [PMID: 29131037]
[10]
Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview. RMD Open 2016; 2(2)e000239
[http://dx.doi.org/10.1136/rmdopen-2015-000239] [PMID: 27493788]
[11]
Galimberti F, Fernandez AP. Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: A rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis? Clin Exp Dermatol 2016; 41(4): 413-6.
[http://dx.doi.org/10.1111/ced.12793] [PMID: 26800651]
[12]
Bustamente L, Buscot M, Marquette CH, Roux C. Sarcoidosis and tocilizumab: Is there a link? Clin Exp Rheumatol 2017; 35(4): 716.
[PMID: 28516883]
[13]
Čarija A, Ivić I, Marasović-Krstulović D, Puizina-Ivić N. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab. Rheumatology (Oxford) 2015; 54(11): 2114-6.
[http://dx.doi.org/10.1093/rheumatology/kev263] [PMID: 26242857]
[14]
Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int 2018; 38(7): 1297-9.
[http://dx.doi.org/10.1007/s00296-018-4034-0] [PMID: 29705819]
[15]
Powell JB, Matthews P, Rattehalli R, et al. Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis. Br J Dermatol 2015; 172(3): 834-6.
[http://dx.doi.org/10.1111/bjd.13365] [PMID: 25141774]
[16]
Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44(5): 1296-307.
[http://dx.doi.org/10.1183/09031936.00000914] [PMID: 25034562]
[17]
Wanat KA, Schaffer A, Richardson V, VanVoorhees A, Rosenbach M. Sarcoidosis and psoriasis: A case series and review of the literature exploring co-incidence vs coincidence. JAMA Dermatol 2013; 149(7): 848-52.
[http://dx.doi.org/10.1001/jamadermatol.2013.4256] [PMID: 23783749]

Rights & Permissions Print Cite
Article Metrics
51
© 2024 Bentham Science Publishers | Privacy Policy